scispace - formally typeset
Z

Zhizheng Wang

Researcher at Central China Normal University

Publications -  12
Citations -  95

Zhizheng Wang is an academic researcher from Central China Normal University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 1, co-authored 1 publications receiving 6 citations.

Papers
More filters
Journal ArticleDOI

Construction of emissive ruthenium(II) metallacycle over 1000 nm wavelength for in vivo biomedical applications

TL;DR: Ru1085 as mentioned in this paper is a metal-based metallacycle with an excitation at 808 nm and emission over 1000 nm, which holds deep optical penetration (up to 6 mm) and enhanced chemo-phototherapy activity.
Journal ArticleDOI

Structural insights into the photoactivation of Arabidopsis CRY2

TL;DR: This study reports the cryogenic electron microscopy structure of a blue-light-activated CRY2 tetramer at a resolution of 3.1 Å, which shows how the CRY1 tetramer assembles and provides insights into blue- light-mediated activation ofCRY2 and a theoretical basis for developing regulators of CRYs for optogenetic manipulation.
Journal ArticleDOI

Exploring the kinase-inhibitor fragment interaction space facilitates the discovery of kinase inhibitor overcoming resistance by mutations

TL;DR: A comprehensive web platform KinaFrag is constructed for the fragment-based kinase inhibitor discovery to overcome resistance, and YT9 shows promising antiproliferative against tumor cells in vitro and effectively inhibits tumor growth in vivo for wild type TRK and TRK mutants.
Journal ArticleDOI

Discovery of Macrocycle-Based HPK1 Inhibitors for T-Cell-Based Immunotherapy.

TL;DR: In this article , a series of macrocycle-based HPK1 inhibitors via a conformational constraint strategy was designed to achieve a higher selectivity to GLK, an HPK homology protein as a positive regulator of T-cell activation.
Journal ArticleDOI

Deciphering Nonbioavailable Substructures Improves the Bioavailability of Antidepressants by Serotonin Transporter.

TL;DR: In this paper , a machine learning model was developed to identify non-bioavailable substructures based on their molecular properties and shows the accuracy of 83.5% in rats by replacing the non-available substructure of approved drug vilazodone.